biostudies-literatureEl Zarif TNCATS NIH HHSNIAID NIH HHSNCI NIH HHSNIH1605-1615https://www.ebi.ac.uk/biostudies/studies/S-EPMC11032703biostudies-literatureUnknown115(12)<h4>Background</h4>Treatment options for penile squamous cell carcinoma are limited. We sought to investigate clinical outcomes and safety profiles of patients with penile squamous cell carcinoma receiving immune checkpoint inhibitors.<h4>Methods</h4>This retrospective study included patients with locally advanced or metastatic penile squamous cell carcinoma receiving immune checkpoint inhibitors between 2015 and 2022 across 24 centers in the United States, Europe, and Asia. Overall survival and progression-free survival were estimated using the Kaplan-Meier method. Objective response rates were determined per Response Evaluation Criteria in Solid Tumours 1.1 criteria. Treatment-related adverse events were graded per the Common Terminology Criteria for Adverse Events, version 5.0. Two-sideJournal of the National Cancer InstituteSafety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors.PMC11032703UG1 CA233328K01 AI163412UL1 TR004419T32 CA247815Maruzzo MSimon NNassar AHRoviello GPettaway CAGheeya JCastellano DRodriguez PAStahlfeld CLee JLButi SAbdel-Wahab NKanesvaran RFarolfi AHahn AWNiglio SVincenzi BPatel VMatthews HFreeman DKim JWApolo ABHui GYang YKhaki ARZhuang TZHarrison MRMcKay RRAdra NEl-Am EDrakaki AVelev MPond GRAppleman LGernone ACortellini APiedra AMilowsky MINecchi ASonpavde GPAntonuzzo Lde Velasco GGlover MTu SMMouhieddine THChoueiri TKGiudice GCBarata PDavis NBNazha BSpiess PEFlippot REl Zarif TMaster VMittra AfalseSafety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors.<h4>Background</h4>Treatment options for penile squamous cell carcinoma are limited. We sought to investigate clinical outcomes and safety profiles of patients with penile squamous cell carcinoma receiving immune checkpoint inhibitors.<h4>Methods</h4>This retrospective study included patients with locally advanced or metastatic penile squamous cell carcinoma receiving immune checkpoint inhibitors between 2015 and 2022 across 24 centers in the United States, Europe, and Asia. Overall survival and progression-free survival were estimated using the Kaplan-Meier method. Objective response rates were determined per Response Evaluation Criteria in Solid Tumours 1.1 criteria. Treatment-related adverse events were graded per the Common Terminology Criteria for Adverse Events, version 5.0. Two-side2023-01-01T00:00:00Z2023 Dec2026-06-01T20:15:04.747Z2026-05-20T03:08:36.099ZS-EPMC110327033756377910.1093/jnci/djad155